PepMetric Technologies Inc. ("PepMetric"), a subsidiary of Pegasus Pharmaceuticals Group Inc. ("Pegasus"), specializes in the therapeutic and diagnostic peptide discovery, for example, design, modification and synthesis of novel peptides, high-throughput array of proteomics biochips, analysis of protein-protein interactions, mapping epitopes of antibodies, identifying interacting peptides to target proteins.  With a huge epitopes sample and peptide sample library, the company offers fast, accurate and economical peptide-based contract research services to both academic and commercial customers.  Having its own research center in the city of Richmond, British Columbia, Canada, the company also collaborates closely in research with several renowned institutes such as the University of British Columbia, the BC Cancer Agency and the Vancouver General Hospital (VGH), as well as with over 10 biotech companies. Using the state-of-the-art technology of "Peptide Array Technology (Pep-Hit)", PepMetric has identified the unique active peptides for inhibiting reverse transcriptase of HIV, carboxypeptidase R, multidrug resistance protein P-GP, complement C5a, tyrosinase, and binding to Tau protein to inhibit polymerization.  These active peptides are promising candidates for novel drug development.  The company is currently focusing on development of HIV drugs and gene therapy.

Website: www.pepmetric.com